| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Maryland Stem Cell Research Fund | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| panCELLa/Implant Therapeutics |
Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan.
We were the first company to offer iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications and were listed on the Japan JASDAQ / Growth stock market in 2013.
REPROCELL and Polyphron announced a collaboration to supply REPROCELL's StemRNA™ iPSCs to Polyphron's artificial human biology platform. The companies aim to advance research by combining iPSC technology with AI-driven tissue manufacturing.
REPROCELL Inc. announced a strategic collaboration with WEIPU Biotechnology Co., Ltd. in Suzhou, China, to provide cell therapy developers with access to StemRNA™ Clinical iPSC technologies and iPSC‑derived mesenchymal stem cell seed and master cell banks, supporting high‑quality clinical starting materials and complementary biological testing services.
REPROCELL Inc. submitted an application in Japan for manufacturing and marketing approval of Stemchymal®, a regenerative medicine product intended to slow the progression of ataxia in patients with SCA3 and SCA6. Steminent Biotherapeutics Inc. of Taiwan will manufacture the product, while REPROCELL will oversee sales and distribution in Japan. Stemchymal® has been designated an orphan drug.
REPROCELL (TYO: 4978) announced that it has received a competitive Commercialization Award from the Maryland Stem Cell Research Fund (MSCRF). The award will fund the development of clinical‑grade, hypoimmune induced pluripotent stem cell (iPSC) seed stocks using REPROCELL’s StemRNA™ reprogramming platform combined with StemEdit technology.
REPROCELL Europe scientists co‑authored a Scientific Reports paper showing that biomedical foundation models combined with multi‑omics feature engineering can enhance drug‑response predictions for inflammatory bowel disease patients. The study, which involved partners from IBM Research Europe and the STFC Hartree Centre, highlights the potential of AI‑driven approaches in personalized IBD treatment.
REPROCELL USA Inc. announced the opening of a new GMP‑compliant cell culture facility on April 7, 2026, enhancing its regenerative medicine manufacturing capabilities. The ceremony was attended by President and Global CEO Dr. Yokoyama, CEO Mr. Rama Modali, and Maryland Lieutenant Governor Aruna Miller. The company continues to produce clinical‑grade iPSCs, including its proprietary StemRNA™ Clinical iPSC Seed Clones, in compliance with FDA, EMA, and PMDA standards.
REPROCELL has launched a US FDA‑compliant GMP Master Cell Bank manufacturing service for human induced pluripotent stem cells (iPSCs). The service, based at its Beltsville, Maryland facility, offers an end‑to‑end workflow that includes StemRNA™ clinical seed production, StemEdit gene‑editing, and GMP MCB production.
REPROCELL announced the addition of the BioThrust™ ComfyCell Incu bioreactor platform to its product catalogue, enhancing its offerings for advanced human cell culture and stem cell research. The 300 mL single‑use system is designed for intensified and scalable cultivation of sensitive cells. As a licensed worldwide distributor, REPROCELL now provides researchers with access to this innovative technology.
REPROCELL announced the commercial launch of StemEdit, its clinical gene editing services and new gene‑edited iPSC product lines that use the AI‑designed OpenCRISPR‑1™ system licensed from Profluent. StemEdit combines REPROCELL’s proprietary clinical gene‑editing technology with StemRNA™ Clinical iPSC Seed Clones, providing GMP‑aligned, traceable, regulatory‑compliant solutions ready for immediate use.
REPROCELL has announced the commercial launch of its StemEdit Hypoimmune hiPSC lines, featuring HLA class I/II knockouts (B2M/CIITA homozygous double KO). The lines are produced using StemEdit gene‑editing technology that employs an alternative to commonly used caspases, offering a precise and IP‑friendly approach. The product line includes StemEdit Human iPSC non‑HLA class 1 (B2M Homo KO) #C5 (RCRP044E) and related variants.